News
Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand.
Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...
Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...
Novo Nordisk currently offers a pill that contains the same active ingredient as its blockbuster Wegovy and Ozempic drugs, but it's marketed to treat diabetes. A higher dose version of the pill to ...
Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and ...
Bloomberg on MSN6h
Novo Nordisk Drops on Weight-Loss Study by Rival LillyNovo Nordisk slumped after a pill from rival Eli Lilly helped patients shed weight and control blood sugar about as well as ...
Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...
Novo Nordisk A/S (NYSE:NVO) is the manufacturer and distributor of pharma products, though the company is mainly known for ...
The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...
Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...
Several hundred units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the Food and Drug Administration.
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results